Literature DB >> 20567828

Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers.

Misti Jain1, Sameer Bakhshi, Abhay A Shukla, Shyam S Chauhan.   

Abstract

The diagnostic and prognostic significance of cathepsin B (CTSB) and L (CTSL) is well documented for solid tumors. However, their significance in acute leukemias is lacking. This study was planned to investigate expression and significance of these proteases in peripheral blood mononuclear cells (PBMCs) of patients with pediatric acute myeloid leukemia (AML). CTSL and CTSB activities were assayed in PBMCs of 24 children with AML and ten healthy controls by spectrofluorimetry. The mRNA levels of these proteases and their specific endogenous inhibitor cystatin C and transcriptional upregulator vascular endothelial growth factor (VEGF) were quantitated by real-time PCR. Correlation analysis of CTSL and CTSB activities/expression with their inhibitor/upregulator and event-free survival (EFS) was done using appropriate statistical tools. CTSL and CTSB protease activity and their mRNA expression were significantly higher in AML patients compared to controls (p ≤ 0.001). A strong positive correlation was observed between VEGF expression and CTSL (r = 0.812; p ≤ 0.001). Similarly, VEGF exhibited a strong positive correlation with CTSB (r = 0.501; p = 0.013). Cystatin expression though significantly high (p ≤ 0.001) in AML was negatively correlated with CTSL (r = -0.920; p ≤ 0.001) and CTSB (r = -0.580, p ≤ 0.001) expression. AML patients with higher CTSL and CTSB activity exhibited an inferior EFS (CTSL: p = 0.045; CTSB: p = 0.002) and overall survival (OS; CTSL: p = 0.05; CTSB: p = 0.004) compared to patients with lower levels of these proteases. This is the first report demonstrating increased expression of CTSL and CTSB in AML, mechanism of their increased expression in relation to VEGF, and their association with poor EFS and OS. These results suggest a potential utility of these proteases as prognostic markers for this malignancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567828     DOI: 10.1007/s00277-010-1012-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Authors:  Dhivya R Sudhan; Maria B Rabaglino; Charles E Wood; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2016-04-07       Impact factor: 5.150

3.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

4.  Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia.

Authors:  Garima Pandey; Sameer Bakhshi; Manoj Kumar; Bhaskar Thakur; Prerna Jain; Punit Kaur; Shyam S Chauhan
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

5.  Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India.

Authors:  Venkatraman Radhakrishnan; Cherian Thampy; Prasanth Ganesan; Rejiv Rajendranath; Trivadi S Ganesan; K R Rajalekshmy; Tenali Gnana Sagar
Journal:  Indian J Hematol Blood Transfus       Date:  2015-09-18       Impact factor: 0.900

6.  Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach.

Authors:  Barbara Depreter; Barbara De Moerloose; Karl Vandepoele; Anne Uyttebroeck; An Van Damme; Eva Terras; Barbara Denys; Laurence Dedeken; Marie-Françoise Dresse; Jutte Van der Werff Ten Bosch; Mattias Hofmans; Jan Philippé; Tim Lammens
Journal:  Pediatr Res       Date:  2020-10-17       Impact factor: 3.756

7.  Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer.

Authors:  Huimin Li; Longxiang Xie; Lin Chen; Lu Zhang; Yali Han; Zhongyi Yan; Xiangqian Guo
Journal:  Aging (Albany NY)       Date:  2020-11-20       Impact factor: 5.682

8.  Clinical significance of serum cathepsin B and cystatin C levels and their ratio in the prognosis of patients with esophageal cancer.

Authors:  Yan Yan; Kun Zhou; Liping Wang; Feng Wang; Xinfeng Chen; Qingxia Fan
Journal:  Onco Targets Ther       Date:  2017-04-03       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.